Sutro Biopharma STRO Increase Decrease In Accrued Expenses And Other Liabilities
Increase Decrease In Accrued Expenses And Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept stro:IncreaseDecreaseInAccruedExpensesAndOtherLiabilities.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's increase decrease in accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's increase decrease in accrued expenses and other liabilities?
- Sutro Biopharma (STRO) reported increase decrease in accrued expenses and other liabilities of $8.4M in Q1 2026.
- How has Sutro Biopharma's increase decrease in accrued expenses and other liabilities changed year-over-year?
- Sutro Biopharma's increase decrease in accrued expenses and other liabilities increased by 51.3% year-over-year, from $5.55M to $8.4M.
- What is the long-term trend for Sutro Biopharma's increase decrease in accrued expenses and other liabilities?
- Over 3 years (2021 to 2024), Sutro Biopharma's increase decrease in accrued expenses and other liabilities has grown at a 7.8% compound annual growth rate (CAGR), from $5.87M to -$7.35M.
- What does increase decrease in accrued expenses and other liabilities mean?
- This measures the net change in liabilities for expenses that have been incurred but not yet paid in cash. An increase indicates that the company is deferring cash outflows, effectively using these liabilities as a source of short-term working capital. Conversely, a decrease indicates the settlement of these obligations, resulting in a cash outflow.